Merck Presents New Data on the Safety and Durable Efficacy of Cladribine Tablets and Advantages of Early Treatment with Rebif® at the 2016 ECTRIMS Congress
- Two oral presentations and nine posters include new analyses on investigational Cladribine Tablets - Real-world data assess the safety, tolerability and effectiveness of Rebif® - Symposium highlights unmet needs among patients with MS and real-word issues - Grant for Multiple Sclerosis Innovation (GMSI) award recipients will share in €1 million